Short answer
Organon & Co (OGN) filed an 8-K current report with the SEC on July 31, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). Q2 2026 results covered quarter ended June 30, 2026, with GAAP financials in Form 10-Q filed July 31, 2026.
Organon & Co 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Q2 2026 results covered quarter ended June 30, 2026, with GAAP financials in Form 10-Q filed July 31, 2026
- Quarterly earnings release and conference call suspended due to pending merger with Sun Pharmaceutical Industries
- Supplemental non-GAAP metrics furnished in Exhibit 99.1 for investor analysis alongside GAAP results
- Merger-driven reporting change reduces customary management commentary and investor access to quarterly updates
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 adjusted net income $230M, down from $261M; adjusted diluted EPS $0.85 vs $1.00
- Six-month adjusted EPS $1.57 vs $2.02, signaling weaker underlying earnings despite GAAP net income rising to $254M
- Q2 adjusted EBITDA $461M, down from $522M; margin compressed to 29.6% from 32.7%
- Six-month adjusted EBITDA $876M vs $1.006B, with margin declining to 29.0% from 32.4%
- Adjustments include $11M of costs tied to the pending Sun Pharmaceutical transaction, plus manufacturing network and restructuring costs
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Organon & Co 8-K filings
Get the next OGN 8-K as it lands
Follow OGN for push alerts, or ask the research agent what this filing means.